(3-Ethyl-phenyl)-oxo-acetaldehyde | 150251-26-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-Ethyl-phenyl)-oxo-acetaldehyde
• 英文别名: 2-(3-Ethylphenyl)-2-oxoacetaldehyde
• CAS: 150251-26-6
• 化学式: C₁₀H₁₀O₂
• 分子量: 162.188
• InChiKey: QSMMILIGCRGLOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-Ethyl-phenyl)-oxo-acetaldehyde 、 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential

  摘要：

  A series of C32-O-aralkyl ether derivatives of the FK-506 related macrolide ascomycin have been prepared based on an earlier reported C32-O-cinnamyl ether design. In the present study, the nature of the aryl tethering group was varied in an attempt to improve oral activity. An imidazol-2-yl-methyl tether was found to be superior among those investigated and has resulted in an ascomycin analog, L-733,725, with in vivo immunosuppressive activity comparable to FK-506 but with an improved therapeutic index. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00397-7

文献信息

• [EN] IMIDAZOLIDYL MACROLIDES
  申请人：MERCK & CO., INC.

  公开号：WO1993005059A1

  公开（公告）日：1993-03-18

  (EN) Imidazolidyl macrolides of general structural formula (I) have been prepared from suitable precursors by alkylation and/or arylation at C-3'' and/or C-4'' of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.(FR) Cette invention concerne des macrolides d'imidazolidyle de formule structurelle générale (I). On a préparé ces macrolides d'imidazolidyle à partir de précurseurs appropriés, par alkylation et/ou arylation au niveau C-3'' et/ou C-4'' du cycle cyclohexyle. Ces immunodépresseurs à base de macrolides sont utiles chez un hôte mammifère pour traiter des maladies auto-immunes et des maladies infectieuses, et pour éviter le rejet des greffes d'organes étrangers et/ou les troubles, les maladies et les maux associés.

  (EN) 通式（I）的咪唑啉基大环内酯已通过在环已环的C-3''和/或C-4''处进行适当的烷基化和/或芳基化反应制备而成。这些大环内酯免疫抑制剂对于治疗自身免疫性疾病、传染病、预防外源性器官移植的排斥以及相关的疾病和疾病方面在哺乳动物宿主中非常有用。 (FR) 通式（I）的咪唑啉基大环内酯已通过在环已环的C-3''和/或C-4''处进行适当的烷基化和/或芳基化反应制备而成。这些大环内酯免疫抑制剂对于治疗自身免疫性疾病、传染病、预防外源性器官移植的排斥以及相关的疾病和疾病方面在哺乳动物宿主中非常有用。
• Imidazolidyl macrolides having immunosuppressive activity
  申请人：MERCK & CO. INC.

  公开号：EP0536896A1

  公开（公告）日：1993-04-14

  Imidazolidyl macrolides of the general structural Formula I: have been prepared from suitable precursors by alkylation and/or arylation at C-3˝ and/or C-4˝ of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.

  一般结构式 I 的咪唑烷基大环内酯： 由合适的前体通过环己基环的 C-3˝ 和/或 C-4˝ 烷基化和/或芳基化制备而成。这些大环内酯类免疫抑制剂可用于哺乳动物宿主治疗自身免疫性疾病、传染性疾病、预防外来器官移植的排斥反应和/或相关的痛苦、疾病和病症。
• US5247076A
  申请人：——

  公开号：US5247076A

  公开（公告）日：1993-09-21
• US5344925A
  申请人：——

  公开号：US5344925A

  公开（公告）日：1994-09-06
• C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential
  作者：Mark T. Goulet、Shelli R. McAlpine、Mary Jo Staruch、Samuel Koprak、Francis J. Dumont、John G. Cryan、Gregory J. Wiederrecht、Raymond Rosa、Mary Beth Wilusz、Laurence B. Peterson、Matthew J. Wyvratt、William H. Parsons

  DOI：10.1016/s0960-894x(98)00397-7

  日期：1998.8

  A series of C32-O-aralkyl ether derivatives of the FK-506 related macrolide ascomycin have been prepared based on an earlier reported C32-O-cinnamyl ether design. In the present study, the nature of the aryl tethering group was varied in an attempt to improve oral activity. An imidazol-2-yl-methyl tether was found to be superior among those investigated and has resulted in an ascomycin analog, L-733,725, with in vivo immunosuppressive activity comparable to FK-506 but with an improved therapeutic index. (C) 1998 Elsevier Science Ltd. All rights reserved.